Atlas Trials

Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors

Clinical trial NCT04767906 · COMPLETED

Trial details

NCT number
NCT04767906
Sponsor
University of Leipzig
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma
Start date
2021-12-14
Primary completion
2024-07-19
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.